References
- Austermann J, Zenker S, Roth J. S100-alarmins: potential therapeutic targets for arthritis. Expert Opin Ther Targets. 2017. 21: 739-751.
- Goyette J, Geczy CL. Inflammation-associated S100 proteins: new mechanisms that regulate function. Amino Acids. 2011. 41: 821-842. https://doi.org/10.1007/s00726-010-0528-0
- Kim IS, Gu A, Lee JS. The role of S100A8 and S100A9 in differentiation of human eosinophilic leukemia cells, EoL-1. Biomed Sci Lett. 2017. 23: 44-47. https://doi.org/10.15616/BSL.2017.23.1.44
- Kim IS, Lee JS. S100A8 and S100A9 secreted by allergens in monocytes inhibit spontaneous apoptosis of normal and asthmatic neutrophils via the Lyn/akt/ERK pathway. Korean J Clin Lab Sci. 2017. 49: 128-134. https://doi.org/10.15324/kjcls.2017.49.2.128
- Laouedj M, Tardif MR, Gil L, Raquil MA, Lachhab A, Pelletier M, Tessier PA, Barabe F. S100A9 induces differentiation of acute myeloid leukemia cells through TLR4. Blood. 2017. 129: 1980-1990. https://doi.org/10.1182/blood-2016-09-738005
- Leanderson T, Liberg D, Ivars F. S100A9 as a Pharmacological Target Molecule in Inflammation and Cancer. Endocr Metab Immune Disord Drug Targets. 2015. 15: 97-104. https://doi.org/10.2174/1871530315666150316123854
- Lee NR, Park BS, Kim SY, Gu A, Kim DH, Lee JS, Kim IS. Cytokine secreted by S100A9 via TLR4 in monocytes delays neutrophil apoptosis by inhibition of caspase 9/3 pathway. Cytokine. 2016. 86: 53-63. https://doi.org/10.1016/j.cyto.2016.07.005
- Lim SY, Yuzhalin AE, Gordon-Weeks AN, Muschel RJ. Tumorinfiltrating monocytes/macrophages promote tumor invasion and migration by upregulating S100A8 and S100A9 expression in cancer cells. Oncogene. 2016. 35: 5735-5745. https://doi.org/10.1038/onc.2016.107
- Mao Y, Poschke I, Kiessling R. Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells. J Intern Med. 2014. 276: 154-170. https://doi.org/10.1111/joim.12229
- Maru Y, Tomita T, Deguchi A, Ieguchi K, Takita M, Tsukahara F, Takemura K, Kitao A, Gusovsky F. Drug Targeting Based on a New Concept-Targeting Against TLR4 as an Example. Endocr Metab Immune Disord Drug Targets. 2015. 15: 83-87. https://doi.org/10.2174/187153031502150522123746
- Moris D, Spartalis E, Angelou A, Margonis GA, Papalambros A, Petrou A, Athanasiou A, Schizas D, Dimitroulis D, Felekouras E. The value of calprotectin S100A8/A9 complex as a biomarker in colorectal cancer: A systematic review. J BUON. 2016. 21: 859-866.
- Nam AR, Kim DH, Kim MJ, Lee JS, Yang SJ, Kim IS. S100A8 induces secretion of MCP-1, IL-6, and IL-8 via TLR4 in Jurkat T cells. Biomed Sci Lett. 2016. 22: 60-64. https://doi.org/10.15616/BSL.2016.22.2.60
- Tsai WC, Tsai ST, Jin YT, Wu LW. Cyclooxygenase-2 is involved in S100A2-mediated tumor suppression in squamous cell carcinoma. Mol Cancer Res. 2006. 4: 539-547. https://doi.org/10.1158/1541-7786.MCR-05-0266
- Weiguo Cui, Nikhil S. Joshi, Ying Liu, Hailong Meng, Steven H Kleinstein, Susan M. Kaech. TLR4 ligands LPS and MPLA differentially regulate effector and memory CD8+ T cell differentiation J Immunol. 2014. 192: 4221-4232. https://doi.org/10.4049/jimmunol.1302569